Online citations, reference lists, and bibliographies.
← Back to Search

MDR1 Inhibition: Less Resistance Or Less Relevance?

L. Garraway, B. Chabner
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The P-glycoprotein (P-gp) family of proteins promotes resistance to cytotoxic agents by increased efflux from within the cell [1]. Numerous clinical studies have correlated expression of MDR1, a P-gp homologue found in human tissues, with increased drug resistance and decreased clinical response in selected haematological malignancies and solid tumours [2,3]. Whether MDR1 is indeed functionally relevant to tumour drug resistance instead of a tantalising epiphenomenon remains uncertain; it is but one of many proteins implicated in the cellular response to chemotherapy. None the less, this protein has been targeted intensely in recent therapeutic strategies aimed at reversing the drug resistance phenotype [4,5]. With this in mind, Davidson and colleagues (this issue) have attempted to sensitise refractory solid tumours to cytotoxic chemotherapy through pharmacological modulation of MDR1 activity. These authors administered a modified EVE regimen (etoposide, vincristine, and epirubicin—each is a MDR1 substrate) along with high-dose cyclosporin, a well-known MDR1 inhibitor, to 16 paediatric patients whose tumours had progressed on therapy or shortly thereafter. The results were modest: two partial responses and 7 patients with short-lived disease stabilisation. Davidson and colleagues add to a growing literature examining MDR1 blockade, including several large clinical trials. Together with previous observations, these data highlight lingering questions regarding the efficacy and clinical relevance of this mechanism, while illustrating several principles and pitfalls of drug resistance modulation and target-based strategies in general. Before considering the clinical data on MDR1 modulation, it is useful to review some key concepts of the target validation process. At minimum, a ‘valid’ protein target must be: (1) expressed or induced in the cancer cells of interest; (2) physiologically active in the appropriate setting; and (3) relevant or limiting with respect to the mechanism being targeted. In clinical trials seeking to validate MDR1 as a drug resistance target, it would therefore seem necessary to confirm its presence and activity within tumours of the study population (this was not done in the Davidson study). To be sure, MDR1 clears such hurdles easily in the preclinical setting; indeed, it represents the principal multidrug-resistance factor in many in vitro systems and animal models [6,7]. At the same time, it is one member of a large family of potential drug resistance modulators ([8,9] Table 1). Other well-known processes (e.g. detoxifying enzymes, apoptosis factors, tumour microenvironment) may also play dominant roles in both intrinsic and acquired resistance [10–14]. Therefore, the validation of MDR1 as a clinical target is not an easy task. None the less, several clinical studies performed during the last decade provided strong evidence linking MDR1 expression and function to a poor response to chemotherapy, particularly in patients with acute myelogenous leukaemia (AML). For example, the Southwest Oncology Group (SWOG) performed both protein expression and functional drug efflux analysis on leukaemic blasts from 211 elderly patients, and found a striking inverse correlation between MDR1 activity and the complete response (CR) rate [2]. A similar study in younger AML patients found that only MDR1 activity, and not other candidate resistance mechanisms, correlated significantly with the CR rate [15]. These data seemed to validate criteria 1 and 2 above for MDR1 as a target for drug resistance reversal.
This paper references
10.1139/O92-054
Glutathione S-transferase in chemotherapy resistance and in carcinogenesis.
R. Schecter (1992)
10.1016/0925-4439(92)90131-6
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines.
D. Nielsen (1992)
10.1038/bjc.1993.277
Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
W. Scheithauer (1993)
10.1146/ANNUREV.PA.36.040196.001113
P-glycoproteins and multidrug resistance.
W. Bellamy (1996)
10.1002/stem.140056
Clinical Reversal of Multidrug Resistance
Susan E. Bates (1996)
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
B. Samuels (1997)
10.1182/BLOOD.V89.9.3323
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
C. Leith (1997)
10.1007/s002800051055
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
B. Sikic (1997)
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
G. Luker (1997)
10.1200/JCO.1997.15.5.1796
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
S. Kornblau (1997)
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
J. Brown (1998)
Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
S. Kaye (1998)
10.1080/10408369891234165
In vivo model systems in P-glycoprotein-mediated multidrug resistance.
W. van de Vrie (1998)
Modulation of multidrug resistance: a paradigm for translational clinical research.
B. Sikic (1999)
10.1002/(SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia
M. Tallman (1999)
10.1016/S0005-2736(99)00167-4
The multidrug resistance protein family.
P. Borst (1999)
10.1182/BLOOD.V94.3.1086.415K32_1086_1099
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
C. Leith (1999)
10.1023/A:1026556119020
Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma.
D. Belpomme (2000)
10.1007/s002800050045
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance
B. Lum (2000)
10.1007/s004419900160
Apoptosis and cancer chemotherapy
G. Makin (2000)
10.1182/BLOOD.V98.12.3212
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
A. List (2001)
10.1002/1615-9861(200110)1:10<1233::AID-PROT1233>3.0.CO;2-2
Proteomics for studying cancer cells and the development of chemoresistance
G. Huetter (2001)
10.1006/SCDB.2000.0250
Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance.
C. Hrycyna (2001)
10.1016/S0092-8674(02)00625-6
Apoptosis A Link between Cancer Genetics and Chemotherapy
R. Johnstone (2002)
10.1146/ANNUREV.MED.53.082901.103929
Mechanisms of cancer drug resistance.
M. Gottesman (2002)



This paper is referenced by
10.1016/j.jbior.2020.100758
Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling.
L. Steelman (2020)
10.3390/cancers12113369
The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes
D. Hu (2020)
10.2147/CMAR.S164766
Using LC–MS/MS-based targeted proteomics to monitor the pattern of ABC transporters expression in the development of drug resistance
Fanqi Meng (2018)
10.1016/j.biopha.2018.02.038
Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
I. Mohammad (2018)
10.1007/978-3-319-42118-6_6
Metabolic Features of Cancer Treatment Resistance.
A. Viale (2016)
10.3906/BIY-1407-3
The role of ABC transporters in anticancer drug transport
S. Karvar (2014)
10.1016/j.addr.2013.09.002
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
A. Sosnik (2013)
10.1158/2159-8290.CD-12-0012
Circumventing cancer drug resistance in the era of personalized medicine.
L. Garraway (2012)
10.1038/nrc2789
ABC transporters in cancer: more than just drug efflux pumps
J. Fletcher (2010)
10.1007/978-3-211-78207-1_5
Preclinical pharmacology and structure-activity studies of epothilones.
K. Altmann (2009)
Multidrug Resistance Protein ( P-Glycoprotein ; MDR 1 )
F. Sharom (2009)
10.1007/978-3-7643-8595-8_6
Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
K. Altmann (2008)
10.1039/B515619J
Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents.
K. Altmann (2007)
10.1007/978-1-59745-035-5_18
Resistance To Taxanes
L. Greenberger (2006)
10.2133/DMPK.20.391
MDR1 genotype-related pharmacokinetics: fact or fiction?
T. Sakaeda (2005)
10.1517/17425255.1.2.219
Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance
N. Cnubben (2005)
10.1053/J.SEMINONCOL.2005.09.008
Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope?
S. Labialle (2005)
Study of novel dual topoisomerase poisons as potential anti-cancer drugs
L. Lewis (2005)
10.1093/NAR/GKH775
Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.
Hyunmin Kang (2004)
10.1517/13543776.14.4.499
Inhibitors of ABC-type drug efflux pumps: an overview of the current patent situation
P. Chiba (2004)
10.1211/0022357044265
A review of selected anti‐tumour therapeutic agents and reasons for multidrug resistance occurrence
M. Sawicka (2004)
10.1517/17410541.1.1.85
Pharmacogenomics of MDR and MRP subfamilies.
N. Okamura (2004)
10.1016/S1368-7646(03)00026-8
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.
H. Broxterman (2003)
10.1042/BJ20020957
Structure and function of efflux pumps that confer resistance to drugs.
M. I. Borges-Walmsley (2003)
10.1016/S0921-4410(03)21032-2
Biology and therapy of malignant solid tumors in childhood.
H. Vandenberg (2002)
Semantic Scholar Logo Some data provided by SemanticScholar